Given its demonstrated benefits in reducing CKD progression and cardiovascular risk, finerenone represents an important therapeutic option for patients with moderate to severe CKD and T2D, particularly those already on optimal renin-angiotensin system (RAS) blockade. This evidence concerns the gene REN and type 2 diabetes mellitus.